A global healthcare company that develops, manufactures and markets pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. I have a holding in my income portfolio (epic code: GSK).
GSK announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for fluticasone furoate/vilanterol (FF/VI) under the proposed brand name RELVAR™ ELLIPTA™ for asthma and chronic obstructive pulmonary disease.
The US FDA has already approved this drug for use back in May of this year and is marketed as BREO ELLIPTA.
GSK, with its current pipeline, has the potential to launch 15 new drugs over the next 3 years and this year has seen good progress in the early stages of achieving this.
Also in a release, that was not a RNS announcement (due to its materiality), GSK stated it had signed a new four-year deal with the U.S. government for $196m to supply inhalation anthrax treatment, raxibacumab, for use in a potential bio-terrorist attack.
No comments:
Post a Comment